Ifosfamide in the elderly: Clinical considerations for a better drug management

Critical Reviews in Oncology/Hematology

Volumn 33, Issue 2, 2000, Pages 129-135

  De Pas, T ^a   Curigliano, G ^a   Catania, C ^a   Comandone, A ^b   De Braud, F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Division of Medical Oncology   (Italy)

Author keywords

Clinical considerations; Elderly; Ifosfamide

Indexed keywords

CHLORAL HYDRATE; CIMETIDINE; IFOSFAMIDE; MESNA; MICROSOME ENZYME; PHENOBARBITAL; PHENYTOIN;

AGED; AGING; BLOOD TOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HEMORRHAGIC CYSTITIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; IFOSFAMIDE; NEOPLASMS;

EID: 0033954846     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00060-8     Document Type: Review

References (70)

1. Levi F., La Vecchia C., Lucchini F., Negri E. Worldwide trends in cancer mortality in the elderly, 1955-1992. Eur. J. Cancer. 32A:1996;652-672.
2. Applegate W.B., Blass J.P., Williams T.F. Instruments for the functional assessment of older patients (a review). N. Engl. J. Med. 322:1990;1207-1214.
3. Kaplan R.M., Bush J.W., Berry C.C. Health status: types of validity and the index of well-being. Health Serv. Res. 11:1976;478-507.
4. Piccirillo J.F., Feinstein A.R. Clinical symptoms and co-morbidity: significance for the prognostic classification of cancer. Cancer. 77:1996;834-842.
5. Rubenstein L.Z., Wieland G.D., Josephson K.R., Rosbrook B., Sayre J., Kane R.L. Improved survival for frail elderly inpatients on a geriatric evaluation unit (GEU): who benefits. J. Clin. Epidemiol. 41(5):1988;441-449.
6. Stuck A.E., Siu A.L., Wieland G.D., Adam J., Rubenstein L.Z. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 342:1993;1032-1036.
7. Reuben D.R. Geriatric assessment in oncology. Cancer. 80(7):1997;1311-1316.
8. Yankic R. Cancer burden in the aged. Cancer. 80(7):1997;1273-1283.
9. Katz S., Ford A.B., Moskowitz R.W. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. J. Am. Med. Assoc. 185:1963;94-99.
10. Rochon P.A., Katz J.N., Morrow L.A. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med. Care. 34:1996;1093-1101.
11. Rockwood K., Fox R.A., Stolee P., Robertson D., Beattle B.L. Frailty in elderly people: an evolving concept. Can. Med. Assoc. J. 150(4):1994;489-495.
12. Fox RA, Puxty J. Geriatric and the problem solving approach. Medicine in the frail elderly: a problem orientated approach. London: Ed. Arnold, 1993.
13. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 9:1969;179-186.
14. Bergman L., Dekker G., van Kerkhoff E.H.M. Influence of age and co-morbidity on treatment choice and survival in elderly patients with breast cancer. Breast Cancer Res. Treat. 18:1991;189-198.
15. Toma S., Palumbo R., Comandone A., Oliva C., Vincenti M., Bumma C., Rosso R. Ambulatory four-day continuous infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumors: A phase I study. Ann. Oncol. 6:1995;193-196.
16. Loeffler T., Weber F., Hausamen T. Ambulatory high-dose 5-day continuous infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. J. Cancer Res. Clin. Oncol. 117(Suppl. 4):1991;S125-S128.
17. Skubitz K., Hamdan H., Thompson R.J. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer. 72(10):1993;2963-2969.
18. Keizer H., Ouwerkerk J., Welvaart K., Van der Velde C., Cleton F. Ifosfamide treatment as a 10-day continuous intravenous infusion. J. Cancer Res. Clin. Oncol. 121:1995;297-302.
19. Guralnik J.M. Assessing the impact of co-morbidity in the older population. Ann. Epidemiol. 6:1996;376-380.
20. Gurland B.J., Cote L.J., Cross P.S., Toner J.A. The assessment of cognitive functions in the elderly. Clin. Geriat. Med. 3:1987;53-63.
21. Kane R. Assessing social function in the elderly. Clin. Geriatr. Med. 3:1987;87-98.
22. Gallangher D. Assessing affect in the elderly. Clin. Geriatr. Med. 3:1987;65-85.
23. Crooks J., O'Malley K., Stevenson I.H. Pharmacokinetics in the elderly. Clin. Pharmacokin. 1:1976;280-296.
24. Vestal R.E., Montamat S.C., Nielson C.P. Drugs in special patient groups: the elderly. Melmon K.L., Morrelli H.F., Hoffmann B.B., Nieremberg D.W. Clinical Pharmacology: Basic Principles in Therapeutics. 1992;851-874 McGraw Hill, New York.
25. Dawling S., Crome P. Clinical pharmacokinetc considerations in the elderly. An update. Clin. Pharmacokin. 17:1989;236-263.
26. Walter-Sack I., Klotz U. Influence of diet and nutritional status on drug metabolism. Clin. Pharmacokin. 31:1996;47-64.
27. Vestal R.E. Aging and pharmacology. Cancer. 80:1997;1302-1310.
28. Durnas C., Loi C.M., Cusack B.J. Hepatic drug metabolism and aging. Clin. Pharmacokin. 19:1990;359-389.
29. Korrapati M.R., Sorkin J.D., Andres R., Muller D.C., Loi C.M., Vessel E.S. Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging. J. Clin. Pharmacol. Ther. 43:1988;436-441.
30. Linderman R.D. Changes in renal function with aging. Implications for treatment. Drugs Aging. 2:1992;423-431.
31. Fleming R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 17(5):1997;146-154.
32. Kaijser G.P., Beijnen J.H., Bult A. Ifosfamide metabolism and pharmacokinetics. Anticancer Res. 14:1994;517-532.
33. Kolow W. Genetic variations in the human hepatic cytochrome P-450 system. Eur. J. Clin. Pharmacol. 31:1987;633-641.
34. Lewis L.D., Fitzgerald D.L., Mohan P. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br. J. Clin. Pharmacol. 31:1991;77-82.
35. Kaijser GP, Keizer HJ, Bejinen JH. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethiylifosfamide in plasma and in urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res. 16:1996;3247-3257.
36. Sarosy G. Ifosfamide. Pharmacologic overview. Semin. Oncol. 16:1989;2-8.
37. Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. Eur. J. Clin. Pharmacol. 31:1987;633-641.
38. Lewis L.D., Fitzgerald D.L., Harper P.G. Fractionated ifosfamide therapy produces a time dependent increase in ifosfamide metabolism. Br. J. Clin. Pharmacol. 30:1990;725-732.
39. Nelson R.L., Allen L.M., Creaven P.J. Pharmacokinetics of divided dose ifosfamide. Clin. Pharmacol. Ther. 19:1976;365-370.
40. Piazza E., Cattaneo M.F., Varini M. Pharmacokinetic studies in lung cancer patients. Cancer. 54:1984;1187-1192.
41. Vessel E.S., Penno M.B. Assessment of methods to identify sources of interindividual pharmacokinetic variation. Clin. Pharmacol. 8:1983;378-409.
42. Allen L.M., Creaven P.J., Nelson R.L. Studies on the human pharmacokinetics of isophosphoramide. Cancer Treat. Rep. 60:1976;451-458.
43. Wagner T., Drings P. Pharmacokinetics and bioavailability of oral ifosfamide. Arzneim. Forsch. 36:1986;878-880.
44. Singer J.M., Hartley J.M., Brennan C. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. Br. J. Cancer. 77:1998;978-984.
45. Rodriguez V., Bodey G.P., Freireich E.J. Reduction of ifosfamide toxicity using dose fractionation. Cancer Res. 36:1976;2945-2948.
46. Brade W.P., Herdrich K., Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 12:1985;1-47.
47. Schoenide S.E., Dana W.J. Ifosfamide and Mesna. Clin. Pharmacol. 9:1990;179-191.
48. Goren M.P., Anthony L.B., Hande K.R. Pharmacokinetics of an intravenous-oral versus intravenous-Masna regimen in lung cancer patients receiving ifosfamide. J. Clin. Oncol. 16:1998;616-621.
49. Brock N., Pohl J. The development of Mesna for regional detoxification. Cancer Trat. Rev. 10:1983;33-43.
50. Duran M., Aarsen G., Fokkens R.H. 2-Mercapto-etanesulfonate-cysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate. A pitfall in the diagnosis of sulfite oxidase deficiency. Clin. Chim. Acta. 111:1981;47-53.
51. Brock N., Hilgard P., Pohl J. Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J. Cancer Res. Clin. Oncol. 108:1984;87-97.
52. Skinner R. Strategies to prevent nephrotoxicity of anticancer drugs. Curr. Opin. Oncol. 7:1995;310-315.
53. Lewis LD, Meanwell CA. Ifosfamide pharmacokinetics and neurotoxicity, Lancet 1990;175-6.
54. Perren T.J., Turner R.C., Smith I.E. Encephalopathy with rapid infusion ifosfamide/Mesna. Lancet. 1:1987;390-391.
55. Danesh M.M., De Giorgio C.M., Beydoun S.R. Ifosfamide encephalopathy. Clin. Toxicol. 27:1989;293-298.
56. Cerny T., Lind M., Thatcher N. et al. A simple outpatient treatment with oral ifosfamide and oral etoposide for patient with small cell lung cancer. Br. J. Cancer. 60:1989;258-261.
57. Cerny T., Kupfer A. The enigma of ifosfamide encephalopathy. Ann. Oncol. 3:1992;679-681.
58. Kupfer A, Aeschlimann C., Wermuth B., Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 343:1994;763-764.
59. Lokiec F., Santoni J., Weill S. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs. 7:1996;893-896.
60. Burns J.J., Conney A. Enzyme stimulation and inhibition in the metabolism of drugs. Proc. R. Soc. Med. 58:1965;955-960.
61. Balducci L., Extermann M. Cancer chemotherapy in the older patient. What the medical oncologist needs to know. Cancer. 80(7):1997;1317-1322.
62. Kimmik G., Fleming R., Muss H., Balducci L. Cancer chemotherapy in older adults: a tolerability perspective. Drugs Aging. 10:1997;34-49.
63. Baker S.D., Grochow L.B. Pharmacology of cancer chemotherapy in the older person. Clin. Geriatr. Med. 13:1997;169-184.
64. Extermann M, Balducci L. Practical proposals for clinical protocols in elderly patients with cancer. In: Balducci L, Lyman GB, Ershler WB. editors. Comprehensive Geriatric Oncology. 2nd ed. Amsterdam: Hardwood, 1998, p. 263-269.
65. Lichtman S.M. Recent developments in the pharmacology of anticancer drugs in the elderly. Curr. Opin. Oncol. 10:1998;572-579.
66. Lind M.J., Margison J.M., Cerny T., Thatcher N., Wilkinson P.M. The effect of age on the pharmacokinetics of ifosfamide. Br. J. Clin. Pharmacol. 30:1990;140-143.
67. Lind M.J., Margison J.M., Cerny T. Prolongation of ifosfamide half-life in obese patients due to altered drug distribution. Cancer Chemother. Pharmacol. 25:1989;139-142.
68. Wagner T., Heydrich D., Jork T. The influence of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites. Arzneim. Forsch. 30:1980;1588-1592.
69. De Pas T, Comandone A, Zampino G, Goldhirsch A, de Braud F. Prolonged infusion of ifosfamide combined with full-dose adriamycin in advanced soft tissue sarcomas. A phase I dose escalation study. ASCO Proceeding Abstract 2092. 1999;18:542a.
70. Frustaci S, Comandone A, Bearz A, Boglione A, Buonadonna A, Stefanovski P, et al. Efficacy and tolerability of an ifosfamide continuous infusion soft tissue sarcoma patient. ASCO Proceeding Abstract 1993. 1999;18:546a.